IMVT Immunovant Inc

Price (delayed)

$39.02

Market cap

$5.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.96

Enterprise value

$5.38B

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights

Immunovant's debt has shrunk by 66% YoY and by 33% QoQ

IMVT's quick ratio is down by 48% year-on-year but it is up by 4.7% since the previous quarter

IMVT's net income is down by 44% YoY and by 4.4% from the previous quarter

The equity has contracted by 36% YoY and by 16% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://immunovant.com

Peers: OMGA

Key stats

What are the main financial stats of IMVT

Market

Shares outstanding

144.66M

Market cap

$5.64B

Enterprise value

$5.38B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

20.25

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$255.42M

EBITDA

-$254.05M

Free cash flow

-$209.82M

Per share

EPS

-$1.96

Free cash flow per share

-$1.6

Book value per share

$1.93

Revenue per share

TBVPS

$2.23

Balance sheet

Total assets

$292.07M

Total liabilities

$40.26M

Debt

$614,000

Equity

$251.81M

Working capital

$250.92M

Liquidity

Debt to equity

Current ratio

7.23

Quick ratio

6.74

Net debt/EBITDA

1.06

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-67.8%

Return on equity

-76.8%

Return on invested capital

N/A

Return on capital employed

-101.4%

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

IMVT stock price

How has the Immunovant stock price performed over time

Intraday

-2.28%

1 week

2.04%

1 month

15.65%

1 year

171.73%

YTD

119.83%

QTD

1.64%

Financial performance

How have Immunovant's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$269.96M

Net income

-$255.26M

Gross margin

N/A

Net margin

N/A

The operating income has dropped by 51% year-on-year and by 4.7% since the previous quarter

IMVT's net income is down by 44% YoY and by 4.4% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation

P/E

N/A

P/B

20.25

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Immunovant's EPS has decreased by 28% YoY and by 2.1% QoQ

The stock's price to book (P/B) is 144% more than its 5-year quarterly average of 8.3 and 107% more than its last 4 quarters average of 9.8

The equity has contracted by 36% YoY and by 16% from the previous quarter

Efficiency

How efficient is Immunovant business performance

IMVT's return on equity has dropped by 96% year-on-year and by 16% since the previous quarter

IMVT's return on assets has dropped by 86% year-on-year and by 14% since the previous quarter

Dividends

What is IMVT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time

IMVT's quick ratio is down by 48% year-on-year but it is up by 4.7% since the previous quarter

Immunovant's current ratio has decreased by 46% YoY but it has increased by 6% QoQ

Immunovant's debt is 100% lower than its equity

Immunovant's debt has shrunk by 66% YoY and by 33% QoQ

The equity has contracted by 36% YoY and by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.